Freenome Plans IPO: Cancer Detection Firm Goes Public
- the Bay Area biotech, a key player in the burgeoning field of liquid biopsy, will list on Nasdaq under the ticker FRNM, aiming to accelerate growth of its...
- Freenome, a biotechnology company based in South San Francisco, California, announced Friday its plans to become a publicly traded company.
- SPACs, also known as "blank check" companies, are formed specifically to raise capital through an initial public offering (IPO) with the purpose of acquiring an existing private company....
“`html
Freenome to Go Public via $330M SPAC Deal, Advancing Multi-Cancer Early Detection
Table of Contents
the Bay Area biotech, a key player in the burgeoning field of liquid biopsy, will list on Nasdaq under the ticker FRNM, aiming to accelerate growth of its AI-powered cancer detection tests.
Published: November 17, 2023 | Last Updated: november 17, 2023
The Deal: Freenome and Perceptive Capital
Freenome, a biotechnology company based in South San Francisco, California, announced Friday its plans to become a publicly traded company. The company will achieve this through a merger with Perceptive Capital Solutions Corp. (Nasdaq: PCSP), a special purpose acquisition company (SPAC). This transaction values Freenome at approximately $330 million and includes a $240 million investment from prominent healthcare investors including Perceptive Advisors, RA Capital, and ADAR1 Capital Management.
SPACs, also known as “blank check” companies, are formed specifically to raise capital through an initial public offering (IPO) with the purpose of acquiring an existing private company. This route to market can be faster than a conventional IPO,but also carries different risks and scrutiny.
Freenome anticipates the merger will be finalized by the first half of 2026, at which point its shares will be listed on the Nasdaq Stock Market under the ticker symbol FRNM.The company detailed the agreement in a press release.
Freenome’s Technology and Clinical Validation
Freenome is focused on developing blood-based tests for the early detection of cancer. Their approach leverages a combination of artificial intelligence (AI) and machine learning (ML) applied to multiomics data - analyzing DNA, RNA, and proteins – to identify cancer signals in the bloodstream. This “liquid biopsy” approach aims to detect cancer before symptoms appear, potentially improving treatment outcomes.
The company highlights the clinical validation of its technology, specifically referencing the pivotal PREEMPT CRC study. This study focused on colorectal cancer and demonstrated promising results in detecting the disease at early stages. Recent findings from the PREEMPT CRC study were also published in the journal of the American Medical Association (JAMA), further bolstering the scientific credibility of Freenome’s platform.
Key PREEMPT CRC Study Data:
| Metric | Result |
|---|---|
| Sensitivity (Detecting Cancer When Present) | 82% |
| Specificity (Correctly Identifying No Cancer) | 81% |
| Negative Predictive Value | 98% |
Source: Freenome press materials and publications related to the PREEMPT CRC study.
The Competitive Landscape of Multi-Cancer Early Detection
Freenome operates in a rapidly evolving and increasingly competitive market. Several companies are vying to develop and commercialize blood-based multi-cancer early detection tests.Key competitors include:
- Grail (Illumina): Leading the field with its Galleri test, which aims to detect over 50 types of cancer.
- Exact Sciences: Known for its Cologuard colorectal cancer screening